A study presented at ESCMID Global 2025 has uncovered the potential of interleukin-6 (IL-6) as a powerful diagnostic biomarker for the early detection of sepsis in high-risk patient groups, including neonates, children and pregnant women. This study is the first to evaluate IL-6’s diagnostic performance in a real-world cohort across all three populations.
Go to Source
https://medicalxpress.com/rss-feed/